Monoclonal Antibody News and Research

RSS
Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.

Further Reading

Experts establish first set of diagnostic criteria for life-threatening idiopathic multicentric CD

Experts establish first set of diagnostic criteria for life-threatening idiopathic multicentric CD

Preterm babies given monoclonal antibody appear less likely to develop recurrent wheeze

Preterm babies given monoclonal antibody appear less likely to develop recurrent wheeze

Study to investigate effectiveness of novel combination treatment for eradicating HIV

Study to investigate effectiveness of novel combination treatment for eradicating HIV

New immunotherapy active against mucosal melanoma and improves survival for bladder cancer patients

New immunotherapy active against mucosal melanoma and improves survival for bladder cancer patients

New biomarker helps better predict survival after surgical removal of colorectal metastases

New biomarker helps better predict survival after surgical removal of colorectal metastases

UCLA-led research finds promising results for more personalized head and neck cancer treatment

UCLA-led research finds promising results for more personalized head and neck cancer treatment

Researchers develop promising therapeutic antibodies against tumor-promoting MMPs

Researchers develop promising therapeutic antibodies against tumor-promoting MMPs

Treatment with biosimilar drug improves progression-free survival in breast cancer patients

Treatment with biosimilar drug improves progression-free survival in breast cancer patients

Combination treatment may be valuable therapeutic option for HER2-negative metastatic breast cancer

Combination treatment may be valuable therapeutic option for HER2-negative metastatic breast cancer

Melanoma drug offers considerable added benefit for patients with advanced NSCLC

Melanoma drug offers considerable added benefit for patients with advanced NSCLC

Results of high-impact clinical trials could improve kidney-related medical care

Results of high-impact clinical trials could improve kidney-related medical care

Allergan, Amgen submit BLA for ABP 215 oncology biosimilar medicine to FDA

Allergan, Amgen submit BLA for ABP 215 oncology biosimilar medicine to FDA

Photoimmunotherapy may be promising treatment option to combat cancer

Photoimmunotherapy may be promising treatment option to combat cancer

Compugen program shows potential for development of new immunotherapy treatments for solid tumors

Compugen program shows potential for development of new immunotherapy treatments for solid tumors

New biologic medication shows promise in treating multi-drug resistant HIV patients

New biologic medication shows promise in treating multi-drug resistant HIV patients

How could emerging technologies impact cancer care?

How could emerging technologies impact cancer care?

Novartis gets three FDA approvals for expanded use of biologic drug to treat rare autoinflammatory diseases

Novartis gets three FDA approvals for expanded use of biologic drug to treat rare autoinflammatory diseases

Novel Trojan Horse antibody strategy may target Ebola's Achilles' heel

Novel Trojan Horse antibody strategy may target Ebola's Achilles' heel

Studies examine effectiveness of nasal sprays in reducing frequency, duration of HHT-related epistaxis

Studies examine effectiveness of nasal sprays in reducing frequency, duration of HHT-related epistaxis

Added benefit not proven for new combination therapy in multiple myeloma

Added benefit not proven for new combination therapy in multiple myeloma